Clinical Trials Browser

Glioma × TIC10 compound × 1 year × Clear all

NCT05580562 2025-08-26

ACTION

Phase 3 Recruiting

Glioma

NCT04617002 2025-08-20

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Approved for marketing

Glioma

NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Phase 2 Terminated

73 enrolled 13 charts 1 FDA

Glioma